title: High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma.
abstract: BACKGROUND
  Interleukin-10 (IL-10) is a inhibiting inflammatory cytokine that plays an important role in immune suppressive microenvironment in multiple myeloma (MM). Whether the level of serum IL-10 could predict treatment response and survival outcomes or not needs to be investigated in MM patients.
  
  
  METHODS
  The level of IL-10 in serum was measured using enzyme-linked immunosorbent assay in 188 patients with newly diagnosed MM.
  
  
  RESULTS
  The best cutoff value for IL-10 in predicting survival is 169.69 pg ml(-1) with an area under the curve (AUC) value of 0.747 (P<0.001). In all, 92 patients (48.9%) were classified as high-IL-10 group (>169.96 pg ml(-1)) and 96 patients (51.1%) as low-IL-10 group (⩽169.96 pg ml(-1)). The overall response rate (ORR) was 79.2% in low-IL-10 group, significantly higher than that in high-IL-10 group (53.3%, P<0.001). Patients in low-IL-10 group had significantly better survival compared with those in high-IL-10 group (3-year PFS rate: 69.3% vs 13.3%, P<0.001; 3-year OS rate: 93.6% vs 51.9%, P<0.001). Multivariate analysis revealed that serum IL-10 level >169.96 pg ml(-1) at diagnosis and certain cytogenetic abnormalities were two adverse factors for PFS and OS.
  
  
  CONCLUSIONS
  Our data suggest that serum IL-10 at diagnosis is a novel, powerful predictor of prognosis for MM.
authors.affiliation: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, People's Republic of China.|Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, People's Republic of China.
authors.forename: Hua
authors.initials: H
authors.lastname: Wang
authors.affiliation: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, People's Republic of China.|Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, People's Republic of China.
authors.forename: Liang
authors.initials: L
authors.lastname: Wang
authors.affiliation: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, People's Republic of China.|Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, People's Republic of China.
authors.forename: Pei-Dong
authors.initials: PD
authors.lastname: Chi
authors.affiliation: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, People's Republic of China.|Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, People's Republic of China.
authors.forename: Wei-da
authors.initials: WD
authors.lastname: Wang
authors.affiliation: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, People's Republic of China.|Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, People's Republic of China.
authors.forename: Xiao-Qin
authors.initials: XQ
authors.lastname: Chen
authors.affiliation: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, People's Republic of China.|Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, People's Republic of China.
authors.forename: Qi-Rong
authors.initials: QR
authors.lastname: Geng
authors.affiliation: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, People's Republic of China.|Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, People's Republic of China.
authors.forename: Zhong-Jun
authors.initials: ZJ
authors.lastname: Xia
authors.affiliation: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, People's Republic of China.|Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, People's Republic of China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Lu
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000175:diagnosis; D011237:Predictive Value of Tests; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; C508609:IL10 protein, human; D016753:Interleukin-10